Smithfield Trust Co. raised its stake in Humana Inc (NYSE:HUM) by 531.2% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 486 shares of the insurance provider’s stock after acquiring an additional 409 shares during the quarter. Smithfield Trust Co.’s holdings in Humana were worth $165,000 at the end of the most recent reporting period.

Other institutional investors also recently added to or reduced their stakes in the company. Alps Advisors Inc. increased its holdings in shares of Humana by 10.0% during the second quarter. Alps Advisors Inc. now owns 3,675 shares of the insurance provider’s stock worth $1,094,000 after purchasing an additional 334 shares during the period. Sio Capital Management LLC bought a new position in shares of Humana during the second quarter worth approximately $5,296,000. Intact Investment Management Inc. bought a new position in shares of Humana during the third quarter worth approximately $220,000. Columbus Hill Capital Management L.P. increased its holdings in shares of Humana by 57.6% during the second quarter. Columbus Hill Capital Management L.P. now owns 150,759 shares of the insurance provider’s stock worth $44,870,000 after purchasing an additional 55,100 shares during the period. Finally, DNB Asset Management AS increased its holdings in shares of Humana by 4.2% during the third quarter. DNB Asset Management AS now owns 30,023 shares of the insurance provider’s stock worth $10,163,000 after purchasing an additional 1,209 shares during the period. 92.62% of the stock is currently owned by hedge funds and other institutional investors.

A number of brokerages recently issued reports on HUM. Morgan Stanley lifted their price objective on shares of Humana from $400.00 to $418.00 and gave the company a “buy” rating in a research note on Thursday. BMO Capital Markets set a $390.00 price objective on shares of Humana and gave the company a “buy” rating in a research note on Thursday. Royal Bank of Canada lifted their price objective on shares of Humana from $318.00 to $349.00 and gave the company a “sector perform” rating in a research note on Thursday. Credit Suisse Group lifted their price objective on shares of Humana from $370.00 to $390.00 and gave the company an “outperform” rating in a research note on Thursday. Finally, Bank of America lifted their price objective on shares of Humana from $400.00 to $415.00 and gave the company a “buy” rating in a research note on Thursday. Seven research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $352.30.

Shares of NYSE:HUM opened at $338.95 on Friday. The company has a market capitalization of $48.77 billion, a P/E ratio of 25.36, a PEG ratio of 1.73 and a beta of 1.03. The company has a current ratio of 1.43, a quick ratio of 1.43 and a debt-to-equity ratio of 0.47. Humana Inc has a 1 year low of $231.90 and a 1 year high of $355.88.

Humana (NYSE:HUM) last issued its earnings results on Wednesday, November 7th. The insurance provider reported $4.58 earnings per share for the quarter, beating analysts’ consensus estimates of $4.29 by $0.29. Humana had a net margin of 2.70% and a return on equity of 19.36%. The firm had revenue of $14.21 billion for the quarter, compared to analyst estimates of $13.97 billion. During the same quarter last year, the business posted $3.39 earnings per share. As a group, equities analysts predict that Humana Inc will post 14.44 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Friday, January 25th. Shareholders of record on Monday, December 31st will be given a $0.50 dividend. The ex-dividend date is Friday, December 28th. This represents a $2.00 dividend on an annualized basis and a yield of 0.59%. Humana’s dividend payout ratio is currently 17.08%.

In other Humana news, insider Elizabeth D. Bierbower sold 3,092 shares of the firm’s stock in a transaction that occurred on Thursday, August 16th. The shares were sold at an average price of $330.00, for a total value of $1,020,360.00. Following the sale, the insider now owns 14,289 shares in the company, valued at $4,715,370. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Bruce D. Broussard sold 18,000 shares of the firm’s stock in a transaction that occurred on Monday, September 10th. The shares were sold at an average price of $328.66, for a total transaction of $5,915,880.00. Following the completion of the sale, the chief executive officer now owns 71,085 shares in the company, valued at approximately $23,362,796.10. The disclosure for this sale can be found here. Company insiders own 0.60% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This piece was originally reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this piece on another website, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The legal version of this piece can be accessed at https://theolympiareport.com/2018/11/10/humana-inc-hum-shares-bought-by-smithfield-trust-co.html.

Humana Profile

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company operates through four segments: Retail; Group and Specialty; Healthcare Services; and Individual Commercial. The Retail segment offers Medicare and supplemental benefit plans to individuals or through group accounts.

Featured Article: Stock Ratings and Recommendations: Understanding Analyst Upgrades and Downgrades

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.